Company news
Kala Bio, Inc. news in 2020
Kala Bio, Inc.'s news releases, calls and decks from 2020, newest first.
Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease
November 15, 2020
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 4, 2020
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
October 26, 2020
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 5, 2020
Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders
June 9, 2020
Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease
May 25, 2020
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 6, 2020
Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease
May 3, 2020
Kala Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares
April 2, 2020
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 9, 2020
Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock
March 9, 2020
Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease
March 8, 2020
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 11, 2020
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
February 5, 2020
Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye Disease
January 14, 2020